I decided to start this thread in view of recent events in the
UK and an exchange of letters between MOH and Mui Hoong, the
Straits Times columnist.
There are now many new anti-cancer drugs that are much more
effective than the ones previously available. At the same time,
there are better and more accurate diagnostic tests that can
predict responsiveness to such newer treatments. However, all of
these are expensive and are not available to most
Singaporeans.
The government does not want to put these drugs into the standard
drug list because they are expensive. So patients in the West with
mammary gland cancer, for example, have a better chance of a cure
because they have access to these newer drugs. On the other hand,
Minister of Health has said that he wants to moderate, not
increase, the expectations of Singaporeans where healthcare is
concerned.
The journalist Chua Mui Hoong is fortunate in that she was given
the drug Herceptin when she developed breast cancer as a
postgraduate student in Harvard. Our patients do not have access to
this drug and it is unlikely to be subsidized by the
government.
As pointed out by another journalist, Herceptin increases the
chance of a cure for early breast cancer from 60% to 80%. That
means 20% pf patients will die from the cancer even with the drug
and 60% will be cured anyway, with or without this new drug. There
are lots of women with early breast cancer now that we are doing
breast screening to pick them up early; and it will cost a lot to
subsidize Herceptin treatment for all of them.
There are many new anti-cancer drugs like Herceptin, some are more
effective and with less side effects. But they are all expensive
and with our budding biomedical industry in Singapore, there is no
way we can follow the Thais and Indians who use local legislation
to make generics, ignoring their patents.
Is it cost effective to pay thousands of dollars just to improve
the cure rate by 20%, even though it is clearly statistically
significant? The question is, what if you fall in that 20%?
Another question that often confronts us: Is it cost-effective to
pay thousands of dollars to increase the lifespan of a cancer
patient by 15 months? What about 12 months? 5 months? 3
months?
What about a drug that does not improve overall survival time but
gives you a better quality of life during that period? Is it
cost-effective to give such a drug?
There are times when I feel disillusioned. My work has contributed
in a small way to improving diagnosis and treatment of cancer; but
only the rich can benefit from it.
If there is interest, perhaps I can use this thread to talk about
some of these newer drugs...
(Just realized that the common word for mammary gland is banned or
something...each time I type'breas_' it turns out gabbage...wonder
why?)